Treatment and Secondary Prophylaxis for Acute Rheumatic Fever
All patients with acute rheumatic fever must receive a full therapeutic course of penicillin to eradicate Group A Streptococcus, followed by continuous long-term antibiotic prophylaxis with intramuscular benzathine penicillin G 1,200,000 units every 4 weeks, with duration determined by presence and severity of cardiac involvement 1.
Initial Treatment
Eradication of Streptococcal Infection
- Administer a complete therapeutic course of penicillin immediately upon diagnosis, even if throat culture is negative at the time 1
- This initial treatment is critical before starting prophylaxis
- Treat any streptococcal infections in family members promptly 1
Anti-inflammatory Therapy
- Use aspirin with or without corticosteroids to control the inflammatory process
- Total duration of anti-inflammatory treatment should be 12 weeks 2
- For severe carditis, glucocorticoids are indicated 3
Secondary Prophylaxis Regimen
Preferred Method: Intramuscular Benzathine Penicillin G
Benzathine penicillin G 1,200,000 units intramuscularly every 4 weeks is the gold standard 1. This regimen is approximately 10 times more effective than oral antibiotics at preventing rheumatic fever recurrence 4. The intramuscular route provides superior protection because it eliminates adherence issues and maintains consistent drug levels 1.
Exception: In high-incidence populations or patients with recurrent ARF despite adherence to every-4-week dosing, administer benzathine penicillin G every 3 weeks 1.
Alternative for Penicillin Allergy
- Erythromycin orally twice daily for non-severe or immediate penicillin hypersensitivity 5
Duration of Secondary Prophylaxis (Critical Decision Algorithm)
The duration depends entirely on cardiac involvement:
With Carditis AND Persistent Valvular Disease:
- 10 years after last ARF episode OR until age 40 (whichever is longer)
- Consider lifelong prophylaxis for high-risk patients (severe valvular disease, high GAS exposure risk)
- Continue prophylaxis even after valve surgery or prosthetic valve replacement 1
With Carditis BUT No Residual Valvular Disease:
- 10 years after last ARF episode OR until age 21 (whichever is longer) 1
Without Carditis:
- 5 years after last ARF episode OR until age 21 (whichever is longer) 1
These recommendations are Class I, Level of Evidence C from the American Heart Association 1.
Important Clinical Considerations
Risk Factors Requiring Extended Prophylaxis
Consider longer prophylaxis duration for patients with:
- Multiple previous ARF attacks
- High exposure to GAS (children, adolescents, parents of young children, teachers, healthcare workers, military recruits, crowded living situations)
- Economically disadvantaged populations 1
Safety Profile
Life-threatening allergic reactions to long-term intramuscular benzathine penicillin G are rare, and the long-term benefits far outweigh the risk of serious allergic reactions 1. However, there is an increased risk of:
- Hypersensitivity reactions (moderate-certainty evidence) 4
- Local injection site reactions (moderate-certainty evidence) 4
- Pain at injection site (use pain-minimizing techniques) 6
Endocarditis Prophylaxis
Patients with RHD receiving benzathine penicillin G prophylaxis still require amoxicillin prophylaxis before high-risk dental or surgical procedures. If recently treated with penicillin/amoxicillin or if immediate penicillin hypersensitivity exists, use clindamycin instead 5.
Common Pitfalls to Avoid
- Do not delay prophylaxis initiation - Start immediately upon diagnosis 1
- Do not discontinue prophylaxis prematurely - Recurrent ARF can occur even with optimal treatment of symptomatic infections 1
- Do not miss asymptomatic GAS infections - These can trigger recurrence, which is why continuous prophylaxis (not just treatment of symptomatic infections) is essential 1
- Do not forget echocardiographic assessment - Clinical examination alone may miss valvular disease; use echo to determine prophylaxis duration 1
- Do not assume oral antibiotics are equivalent - Intramuscular benzathine penicillin G is substantially superior (RR 0.07) 4